BioLife Solutions, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $34.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jason McCarthy’s rating is based on BioLife Solutions’ strategic focus on high-margin cell processing tools, which is evident from their recent divestiture of the evo cold chain logistics business for $25.5 million. This move allows the company to concentrate on its core strengths and improve profitability. The company’s third-quarter results showed a significant year-over-year revenue increase of 31%, surpassing market expectations and demonstrating strong financial performance.
Additionally, BioLife Solutions has increased its revenue guidance for cell processing, reflecting confidence in its growth trajectory. The company is also capitalizing on the expanding cell and gene therapy market, with its media being used in numerous approved therapies and ongoing clinical studies. With a robust cash position post-divestiture, BioLife is well-positioned to explore further growth opportunities, including potential small-scale acquisitions that align with its strategic focus.
In another report released yesterday, Craig-Hallum also reiterated a Buy rating on the stock with a $0.00 price target.
Based on the recent corporate insider activity of 107 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BLFS in relation to earlier this year.